Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system

Michelle M.A. Kip, Sytze de Roock, Gillian Currie, Deborah A. Marshall, Luiza R. Grazziotin, Marinka Twilt, Rae S.M. Yeung, Susanne M. Benseler, Maud A. Schreijer, Sebastiaan J. Vastert, Nico Wulffraat, Annet van Royen-Kerkhof, Joost F. Swart, Maarten J. IJzerman*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
45 Downloads (Pure)

Abstract

Background: This study aims to quantify medication costs in juvenile idiopathic arthritis (JIA), based on subtype. Research design and methods: This study is a single-center, retrospective analysis of prospective data from electronic medical records of JIA patients, aged 0–18 years between 1 April 2011 and 31 March 2019. Patient characteristics (age, gender, subtype) and medication use were extracted. Medication use and costs were reported as: 1) mean total annual costs; 2) between-patient heterogeneity in these costs; 3) duration of medication use; and, 4) costs over the treatment course. Results: The analysis included 691 patients. Mean total medication costs were €2,103/patient/year, including €1,930/patient/year (91.8%) spent on biologicals. Costs varied considerably between subtypes, with polyarticular rheumatoid-factor positive and systemic JIA patients having the highest mean costs (€5,020/patient/year and €4,790/patient/year, respectively). Mean annual medication costs over the patient’s treatment course ranged from <€1,000/year (71.1% of patients) to >€11,000/year (2.5% of patients). Etanercept and adalimumab were the most commonly used biologicals. Cost fluctuations over the treatment course were primarily attributable to biological use. Conclusions: Polyarticular rheumatoid-factor positive and systemic JIA patients had the highest mean total annual medication costs, primarily attributable to biologicals. Costs varied considerably between subtypes, individuals, and over the treatment course.

Original languageEnglish
Pages (from-to)975-984
Number of pages10
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume21
Issue number5
Early online date29 Dec 2020
DOIs
Publication statusPublished - 3 Sep 2021

Keywords

  • Health care costs
  • health resources
  • juvenile idiopathic arthritis
  • treatment costs

Fingerprint

Dive into the research topics of 'Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system'. Together they form a unique fingerprint.

Cite this